Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

Udai Banerji(Institute of Cancer Research), Carla M.L. van Herpen(Radboud University Nijmegen), Cristina Saura(Vall d'Hebron Institute of Oncology), Fiona Thistlethwaite(The Christie NHS Foundation Trust), Simon Lord(Churchill Hospital), Víctor Moreno, Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Valentina Boni, Christian Rolfo(U-M Rogel Cancer Center), Elisabeth G.E. de Vries(University Medical Center Groningen), Sylvie Rottey(Ghent University Hospital), Jill J.J. Geenen(The Netherlands Cancer Institute), Ferry A.L.M. Eskens(Erasmus MC), Marta Gil-Martín(Institut Català d'Oncologia), Ellen C.M. Mommers(Synthon (Netherlands)), N.P. Koper(Synthon (Netherlands)), Philippe Aftimos(Institut Jules Bordet)
The Lancet Oncology
June 27, 2019
Cited by 559Open Access
Full Text

Abstract


Related Papers

No related papers found

Powered by citation graph analysis